Terms ending in 2039
Every in-force patent on Genmab A/S's record whose computed term ends in 2039, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 12,448,459 | Bispecific ANTI-CD37 Antibodies, Monoclonal ANTI-CD37 Antibodies and Methods of Use Thereof In force · Medium confidence | Genmab A/S | In force | Medium confidence | |
| US 11,008,399 | Antibodies In force · High confidence | Genmab A/S | In force | High confidence | |
| US 11,130,819 | Antibodies In force · High confidence | Genmab A/S | In force | High confidence | |
| US 12,617,854 | Humanized or Chimeric CD3 Antibodies In force · Medium confidence | Genmab A/S | In force | Medium confidence |
4 of 4 patents shown. Soonest term end first, then patent number.
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.